In Silico Identification of Significant Detrimental Missense Mutations of EGFR and Their Effect with 4-Anilinoquinazoline-Based Drugs
- 239 Downloads
In this work, we identified the detrimental missense mutations (point mutations) in epidermal growth factor receptor (EGFR) and its binding efficiency with the inhibitors namely Erlotinib, Gefitinib, and Lapatinib. Out of 26 point mutations on EGFR, 12 point mutations were commonly less stable, deleterious, and damaged as shown by all the three servers, I-Mutant2.0, SIFT, and PolyPhen. Further, we modeled 12 mutants and superimposed with the native EGFR to get RMSD values. Docking studies showed that Erlotinib had lesser binding affinity against both native and all the 12 mutants. Gefitinib had maximum binding affinity only with two mutants, viz., R748P and L858R. Lapatinib had maximum binding affinity with both native and other 10 mutants. Based on our computational analysis, we recommend that the combined administration of Gefitinib and Lapatinib could give a better effect in combating the disease.
KeywordsPoint mutation EGFR Erlotinib Gefitinib Lapatinib
The authors thank the management of Vellore Institute of Technology for providing the facilities to carry out this work.
- 4.Pollack, V. A., et al. (1999). The Journal of Pharmacology and Experimental Therapeutics, 291(2), 739–748.Google Scholar
- 5.Wakeling, A. E., et al. (2002). Cancer Research, 62(20), 5749–5754.Google Scholar
- 6.Rusnak, D. W., et al. (2001). Molecular Cancer Therapeutics, 1(2), 85–94.Google Scholar
- 10.Rusnak, D. W., et al. (2001). Cancer Research, 61(19), 7196–7203.Google Scholar
- 29.Duhovny, D., et al. (2002). Lecture Notes in Computer Science 2452 (pp. 185–200). New York: Springer.Google Scholar